Company intelligence / Profile preview

NeuroBionics

Somerville, Massachusetts, United Statesneurobionics.io ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

NeuroBionics has developed a minimally invasive endovascular neuromodulation platform using hair-thin flexible fibers that can record and stimulate neural activity. The approach aims to revolutionize deep brain stimulation by avoiding open-brain surgery. The company is preclinical but has secured significant seed funding and published foundational research in top journals. No clinical results are available yet.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceBioelectronic medicine (bioelectronic device)Neuromodulation device
Industry: Therapeutic Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025.Notable investors include Dolby Family Ventures and Dr. Thomas Insel.

Beyond the preview

Go deeper on NeuroBionics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroBionics.

Explore the full profile